Hikma Pharmaceuticals (LON:HIK) Given “Buy” Rating at Deutsche Bank Aktiengesellschaft

Deutsche Bank Aktiengesellschaft reiterated their buy rating on shares of Hikma Pharmaceuticals (LON:HIK) in a research note issued to investors on Friday morning,Digital Look reports. They currently have a GBX 1,950 target price on the stock.

A number of other equities research analysts have also recently issued reports on HIK. Berenberg Bank reiterated a “buy” rating and issued a GBX 1,800 price objective on shares of Hikma Pharmaceuticals in a report on Tuesday, April 28th. Citigroup restated a “buy” rating on shares of Hikma Pharmaceuticals in a report on Thursday, July 16th. Finally, Jefferies Financial Group boosted their price target on Hikma Pharmaceuticals from GBX 1,850 to GBX 1,870 and gave the stock a “buy” rating in a research report on Tuesday, May 5th. Six equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Hikma Pharmaceuticals currently has a consensus rating of “Buy” and an average target price of GBX 2,038.

Hikma Pharmaceuticals Stock Performance

Shares of HIK opened at GBX 1,677 on Friday. The company’s fifty day moving average is GBX 1,533.91 and its 200-day moving average is GBX 1,453.32. Hikma Pharmaceuticals has a 12 month low of GBX 1,187 and a 12 month high of GBX 1,865. The firm has a market cap of £3.50 billion, a price-to-earnings ratio of 9.27, a price-to-earnings-growth ratio of 2.38 and a beta of 0.65. The company has a quick ratio of 1.27, a current ratio of 1.82 and a debt-to-equity ratio of 61.84.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.